Fierce Pharma Asia—Amgen, Kyowa’s OX40 divorce; Roche’s RNAi deal; Daiichi’s ADC cull

Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. | Amgen added to uncertainty surrounding the OX40 drug class by returning an autoimmune candidate to Kyowa Kirin. Roche penned a deal worth up to $1.7 billion for an RNA interference program from SanegeneBio. Daiichi Sankyo stopped development of its first non-DXd candidate. And more.Read More